Capryloylglycine

We are Capryloylglycine CAS:14246-53-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 14246-53-8
Product Name: Capryloylglycine
Other Name:
Capryloylglycine
2-(octanoylamino)acetic acid
N-n-octanoylglycine
2-octanamidoacetic acid
N-(1-oxooctyl)-Glycine
N-Octanoylglycine
 
Density: 1.0±0.1 g/cm3
Boiling Point: 403.9±28.0 °C at 760 mmHg
Molecular Formula: C10H19NO3
Molecular Weight: 201.263
Flash Point: 198.1±24.0 °C
Exact Mass: 201.136490
PSA: 66.40000
LogP: 1.78
Vapour Pressure: 0.0±2.0 mmHg at 25°C
Index of Refraction: 1.464
 
Specification
Appearance: White or off-white crystalline powder
Identification: The infrared spectrum of this product should be consistent with the reference.
Loss on drying: ≤1.0%
Ignition residue ≤0.1%
Heavy metal: ≤20ppm
Assay: ≥98.0%
 
Application
Creams and lotions for anti-acne, anti-aging and advanced skin care products.
N-Octanoylglycine is a derivative of Glycine and is an amphiphilic lipoamino acid commonly used in cosmetics for its antibacterial properties. N-Octanoylglycine is the active ingredient in products designed to treat seborrheic dermatitis on the scalp and acne prone skin.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

Capryloylglycine


Related News: The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.2- (1H-1,2,4-Triazol-1-il) -2 ', 4'-difluoroacetofenona CAS:86404-63-9 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.107-29-9 The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route.17689-77-9 There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.The Company’s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs).

Related Products
Product Name
Ethyl 3-chloro-4-fluorobenzoate View Details
4-Chloro-3-nitrobenzonitrile View Details
benzododecinium chloride Cas:139-07-1 View Details
1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butane-1,3-dione manufacturer N-(4-bromophenyl)-N-phenyl-[1,1’-biphenyl]-4-amine manufacturer N-[2-(4-nitrophenoxy)ethyl]-2-(4-nitrophenyl)ethanamine manufacturer 2,5-Dimethyl-1,4-dithiane-2,5-diol manufacturer 1-chloro-4-fluoro-2-nitrobenzene manufacturer